LadRx (STU:CX5) Total Liabilities: €2.22 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CX5 LadRx Corp STU:CX5
40 GF Score
Price €0.06
View Full Analysis

What is LadRx Total Liabilities?

LadRx STU:CX5 40 Total Liabilities is €2.22 Mil as of Mar. 2025. GuruFocus rates STU:CX5 with a GF Score™ of 40/100.

LadRx's Total Liabilities for the quarter that ended in Mar. 2025 was €2.22 Mil.

LadRx's quarterly Total Liabilities increased from Sep. 2024 (€1.65 Mil) to Dec. 2024 (€2.16 Mil) and increased from Dec. 2024 (€2.16 Mil) to Mar. 2025 (€2.22 Mil).

LadRx's annual Total Liabilities declined from Dec. 2022 (€2.10 Mil) to Dec. 2023 (€2.02 Mil) but then increased from Dec. 2023 (€2.02 Mil) to Dec. 2024 (€2.16 Mil).


LadRx Total Liabilities Historical Data

* Premium members only.

The historical data trend for LadRx's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LadRx Total Liabilities Chart

LadRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.62 3.50 2.10 2.02 2.16

LadRx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.73 1.70 1.65 2.16 2.22
STU:CX5
40GF Score
LadRx Corp STU:CX5
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LadRx Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

LadRx's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=0.802--1.355
=2.16

LadRx's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities=Total Assets (Q: Mar. 2025 )-Total Equity (Q: Mar. 2025 )
=0.24--1.975
=2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €2.22 Mil mean?
LadRx (STU:CX5) has a Total Liabilities of €2.22 Mil as of Mar. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LadRx and its competitors.
Is LadRx's Total Liabilities too high?
LadRx's current Total Liabilities is €2.22 Mil. Overall, LadRx has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does LadRx's Total Liabilities compare to VRTX and REGN?
LadRx's Total Liabilities of €2.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LadRx and its competitors. LadRx's current Total Liabilities is €2.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LadRx stock overvalued right now?
LadRx (STU:CX5) has a current Total Liabilities of €2.22 Mil. The current Total Liabilities is €2.22 Mil. LadRx's overall GF Score™ is 40/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For LadRx (STU:CX5), the current Total Liabilities is €2.22 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LadRx Business Description

Address 11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
40GF Score

Get the complete analysis for STU:CX5

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price